Pompe Disease Treatment Market Size, Growth Forecasts 2032

Pompe Disease Treatment Market Size – By Treatment Type (ERT, Supportive Care), By Disease Type (Infantile, Juvenile), By Therapy Type (Monotherapy, Combination Therapy), By End-user (Hospitals, Infusion Care) & Forecast, 2024 ­ 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Data validation

1.4&nbsp;&nbsp;&nbsp; Forecast parameters

1.5&nbsp;&nbsp;&nbsp; Data sources

1.5.1&nbsp;&nbsp;&nbsp; Primary

1.5.2&nbsp;&nbsp;&nbsp; Secondary

1.5.2.1&nbsp;&nbsp;&nbsp; Paid sources

1.5.2.2&nbsp;&nbsp;&nbsp; Public sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Growing incidence of pompe disease

3.2.1.2&nbsp;&nbsp;&nbsp; Expanding R&amp;D efforts

3.2.1.3&nbsp;&nbsp;&nbsp; Growing regulatory support

3.2.1.4&nbsp;&nbsp;&nbsp; Increasing emphasis on early diagnosis advancement

3.2.1.5&nbsp;&nbsp;&nbsp; Favorable reimbursement policies

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Limited treatment options

3.2.2.2&nbsp;&nbsp;&nbsp; High treatment costs

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Pipeline assessment

3.5&nbsp;&nbsp;&nbsp; Reimbursement scenario

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.7&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.7.1&nbsp;&nbsp;&nbsp; Supplier power

3.7.2&nbsp;&nbsp;&nbsp; Buyer power

3.7.3&nbsp;&nbsp;&nbsp; Threat of new entrants

3.7.4&nbsp;&nbsp;&nbsp; Threat of substitutes

3.7.5&nbsp;&nbsp;&nbsp; Industry rivalry

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategic dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Treatment Type, 2018 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Enzyme replacement therapy (ERT)

5.3&nbsp;&nbsp;&nbsp; Supportive care

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Disease Type, 2018 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Infantile

6.3&nbsp;&nbsp;&nbsp; Juvenile

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Therapy, 2018 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Monotherapy

7.3&nbsp;&nbsp;&nbsp; Combination therapy

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End-User, 2018 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Hospitals

8.3&nbsp;&nbsp;&nbsp; Infusion centers

8.4&nbsp;&nbsp;&nbsp; Other end-users

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2018 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends, by region

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; Japan

9.4.2&nbsp;&nbsp;&nbsp; China

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

9.6&nbsp;&nbsp;&nbsp; Middle East and Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; Abeona Therapeutics Inc.

10.2&nbsp;&nbsp;&nbsp; Amicus Therapeutics, Inc.

10.3&nbsp;&nbsp;&nbsp; Aro Biotherapeutics Company

10.4&nbsp;&nbsp;&nbsp; Audentes Therapeutics (Astellas Pharma Inc.)

10.5&nbsp;&nbsp;&nbsp; Bayer AG

10.6&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd.

10.7&nbsp;&nbsp;&nbsp; Genethon

10.8&nbsp;&nbsp;&nbsp; Maze Therapeutics

10.9&nbsp;&nbsp;&nbsp; M6P Therapeutics

10.10&nbsp;&nbsp;&nbsp; Oxyrane

10.11&nbsp;&nbsp;&nbsp; Sanofi

10.12&nbsp;&nbsp;&nbsp; Valerion Therapeutics 
&nbsp;

Pompe Disease Treatment Market

Get a free sample of this report